Latest Ribavirin Stories
BERLIN and RIDGEFIELD, Conn., April 1, 2011 /PRNewswire/ -- New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat.
HUDDINGE, Sweden, April 1, 2011 /PRNewswire-FirstCall/ -- - Results Show Potent Antiviral Efficacy of Once Daily 150 mg TMC435 in Hepatitis C Patients Who Have Failed Earlier Treatment, Especially in Prior Null Responders, and Excellent Safety and Tolerability Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner, Tibotec has presented the results of a planned Week 24 interim analysis of the...
Adverse event profile of regimen containing BMS-790052 was consistent with that of treatment with PEG-Interferon alfa and ribavirin alone Princeton, NJ (PRWEB) March 31, 2011 Bristol-Myers Squibb Company(NYSE: BMY) today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral (DAA) BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin (RBV), achieved sustained virologic response 12...
New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C (HCV).
A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen.
PRINCETON, N.J., March 30, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV).
CORK, Ireland, March 29, 2011 /PRNewswire/ -- Tibotec Pharmaceuticals announced today that four abstracts reporting research findings with TMC435, the company's investigational hepatitis C protease inhibitor, have been accepted for presentation at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) in Berlin, Germany, March 30 to April 3, 2011.
SAN DIEGO, March 15, 2011 /PRNewswire/ -- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection (HCV).
BLUE BELL, Pa., March 14, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc.
SAN DIEGO, March 11, 2011 /PRNewswire/ -- Conatus Pharmaceuticals Inc.
Lassa fever, first described in 1969 in Lassa, is an acute viral hemorrhagic fever. Clinical cases were known a decade before this but were not associated with this viral pathogen. It is endemic in West African countries and causes approximately 5,000 deaths. The Natal Multimammate Mouse is the primary animal host. The rodent is a source of protein but the virus is usually transmitted by the contact with the feces and urine of animals accessing grain stores in residences. The lassa virus...
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.